<DOC>
	<DOCNO>NCT03045029</DOCNO>
	<brief_summary>This prospective , observational , multicenter , patient registry observe ass real-world use tolerability Orenitram ( treprostinil ) . Patients newly initiate Orenitram treatment pulmonary arterial hypertension ( PAH ) transition another prostacyclin therapy evaluate 52 week observe dose regimen , titration schedule , prostacyclin-related adverse event ( AEs ) , clinical outcome interest .</brief_summary>
	<brief_title>ADAPT - A Patient Registry Real-world Use OrenitramÂ®</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Treprostinil</mesh_term>
	<criteria>1 . The patient newly prescribe Orenitram , per package insert indication , plan initiate therapy medication , receive Orenitram 21 few day . 2 . The patient agree dose , prostacyclinrelated AE interest record keep , survey participation designate time period , record medication change use duration study . 3 . The patient ability answer survey , use diary English , access internet . 1 . The patient previously receive Orenitram 21 day . 2 . The patient currently receive epoprostenol therapy receive epoprostenol within 30 day enrollment ( except receive acute vasodilator test ) . 3 . The patient currently participate investigational drug device study within 30 day enrollment . Coenrollment noninterventional study allow .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>PAH</keyword>
	<keyword>Oral Treprostiinil</keyword>
	<keyword>Orenitram</keyword>
</DOC>